EP0888381A4 - Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation - Google Patents
Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisationInfo
- Publication number
- EP0888381A4 EP0888381A4 EP96945796A EP96945796A EP0888381A4 EP 0888381 A4 EP0888381 A4 EP 0888381A4 EP 96945796 A EP96945796 A EP 96945796A EP 96945796 A EP96945796 A EP 96945796A EP 0888381 A4 EP0888381 A4 EP 0888381A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- making
- methods
- same
- diagnostic agents
- targeted therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US902895P | 1995-12-21 | 1995-12-21 | |
US9028P | 1995-12-21 | ||
PCT/US1996/020577 WO1997039021A1 (fr) | 1995-12-21 | 1996-12-19 | Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0888381A1 EP0888381A1 (fr) | 1999-01-07 |
EP0888381A4 true EP0888381A4 (fr) | 2001-10-17 |
Family
ID=21735166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96945796A Ceased EP0888381A4 (fr) | 1995-12-21 | 1996-12-19 | Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0888381A4 (fr) |
JP (1) | JP2000506854A (fr) |
AU (1) | AU1821397A (fr) |
CA (1) | CA2241051A1 (fr) |
WO (1) | WO1997039021A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180084B1 (en) | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
EP1235595B8 (fr) * | 1999-09-08 | 2009-10-07 | Bayer Schering Pharma Aktiengesellschaft | Ciblage de medicament induit par l'integrine |
GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
US7589061B2 (en) | 2001-04-23 | 2009-09-15 | Mallinckrodt Inc. | Tc and Re labeler radioactive glycosylated octreotide derivatives |
WO2007003010A1 (fr) * | 2005-07-05 | 2007-01-11 | Baker Medical Research Institute | Agent anticoagulant et son utilisation |
US20080267949A1 (en) * | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1339445C (fr) * | 1986-11-12 | 1997-09-09 | The General Hospital Corporation | Molecules d'immunoglobuline hybride recombinante et methode d'utilisation |
CA2074825C (fr) * | 1990-12-14 | 2005-04-12 | Daniel J. Capon | Chaines chimeriques pour cheminements de signaux de recepteurs |
US5817767A (en) * | 1993-02-24 | 1998-10-06 | Progenics Pharmaceuticals, Inc. | Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same |
-
1996
- 1996-12-19 AU AU18213/97A patent/AU1821397A/en not_active Abandoned
- 1996-12-19 CA CA002241051A patent/CA2241051A1/fr not_active Abandoned
- 1996-12-19 EP EP96945796A patent/EP0888381A4/fr not_active Ceased
- 1996-12-19 JP JP09532094A patent/JP2000506854A/ja not_active Ceased
- 1996-12-19 WO PCT/US1996/020577 patent/WO1997039021A1/fr not_active Application Discontinuation
Non-Patent Citations (7)
Also Published As
Publication number | Publication date |
---|---|
WO1997039021A1 (fr) | 1997-10-23 |
AU1821397A (en) | 1997-11-07 |
JP2000506854A (ja) | 2000-06-06 |
EP0888381A1 (fr) | 1999-01-07 |
CA2241051A1 (fr) | 1997-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0959908A4 (fr) | Nouveaux milieux de contraste contenant un agent de ciblage, a usage diagnostique et therapeutique | |
HUP9902068A3 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
PL330235A1 (en) | Derivatives of spiropiperidine and their application as therapeutic agents | |
PL323087A1 (en) | Methods of and formulations for modulating human sexual response | |
EP0831904A4 (fr) | Traitement et diagnostic du cancer de la prostate | |
ZA967029B (en) | Versatile stereotactic device and methods of use | |
IL114331A0 (en) | Medical use of bromelain | |
ZA96610B (en) | Preparation of n-aryl and n-hetaryhydroxylamines | |
EP0888381A4 (fr) | Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation | |
HUP9900147A3 (en) | Therapeutic agents and autoimmune diseases | |
ZA971607B (en) | Methods of treatment of allergic diseases | |
GB9526691D0 (en) | Medical use of proteases | |
PL322002A1 (en) | Variants of human dnase i | |
EP1009433A4 (fr) | Composition therapeutique et procede de traitement | |
ZA951485B (en) | Medical application of bromelain | |
EP0833641A4 (fr) | Traitement et prevention de maladies prostatiques | |
PL312146A1 (en) | Novel acylated pseudopetides with thrifluoromethy-substituted 2-azabicyclooctane, method of obtaining and therapeutic agents containing them | |
EP1015559A4 (fr) | Serfine-1 (rasp-1) associee a la regeneration humaine et methodes d'utilisation | |
GB9516572D0 (en) | Prevention and/or treatment of disease | |
IL123509A0 (en) | Therapeutic lipidic vesicles methods of use and compositions | |
GB9523066D0 (en) | Compounds and their therapeutic use | |
PL312147A1 (en) | Novel acylated pseudopeptides with thrifluoromethyl-substituted 2-azabicyclooctane, method of obtaining and therapeutic agents containing them | |
GB9525891D0 (en) | Therapeutic agents and their preparation | |
ZA968902B (en) | Methods and compositions for treatment of diseases | |
PL307711A1 (en) | Imidazodiazepins, method of obtaining them and therapeutic agents containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980717 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE DK FR GB IT LI NL SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07K 1/00 A, 7C 07K 14/00 B, 7C 07K 16/00 B, 7C 07K 17/00 B, 7C 12P 21/02 B, 7C 12P 21/04 B, 7C 12P 21/08 B, 7A 61K 39/395 B, 7A 61K 39/40 B, 7A 61K 39/42 B, 7A 61K 47/48 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20010904 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): BE CH DE DK FR GB IT LI NL SE |
|
17Q | First examination report despatched |
Effective date: 20020419 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20050417 |